Form 4: Heron Therapeutics CEO Craig Collard Reports Stock Transactions
SEC Form 4
Craig Collard, CEO of Heron Therapeutics, reports the disposition of 34,789 shares of common stock on April 30, 2025, through the vesting of restricted stock units.
Summary
- On April 30, 2025, Craig Collard, the CEO of Heron Therapeutics, reported a transaction involving the company's stock.
- Collard disposed of 34,789 shares of common stock.
- This disposition occurred through the vesting of restricted stock units.
- Following the transaction, Collard directly owns 425,952 shares of common stock.
- Collard also directly owns 521,831 derivative securities in the form of restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions by an insider, with no inherent positive or negative implications.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider trading activity.
Key Dates
| Date | Description |
|---|---|
| 01/31/2025 | Date of grant for restricted stock units, vesting in 16 equal installments beginning one quarter after this date. |
| 04/30/2025 | Date of transaction: Disposition of 34,789 shares of common stock due to vesting of restricted stock units. |
| 05/02/2025 | Date of signature on the Form 4 filing. |
Keywords
Heron Therapeutics, Craig Collard, stock transaction, Form 4, restricted stock units, beneficial ownership, HRTX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.